196204-01-0

Basic information

• Product Name: 4-PIPERIDIN-4-YL-BENZOIC ACID
• Synonyms: 4-(4'-CARBOXYPHENYL)PIPERIDINE;4-PIPERIDIN-4-YL-BENZOIC ACID;Benzoic acid, 4-(4-piperidinyl)-
• CAS NO: 196204-01-0
• Molecular Formula: C₁₂H₁₅NO₂
• Molecular Weight: 205.25
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;pharmacetical
• Mol File: 196204-01-0.mol

Chemical Properties

• Boiling Point: 372.142 °C at 760 mmHg
• Flash Point: 178.865 °C
• Appearance: /
• Density: 1.145
• Vapor Pressure: 3.38E-06mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: 2-8°C
• PKA: 4.25±0.10(Predicted)
• CAS DataBase Reference: 4-PIPERIDIN-4-YL-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERIDIN-4-YL-BENZOIC ACID(196204-01-0)
• EPA Substance Registry System: 4-PIPERIDIN-4-YL-BENZOIC ACID(196204-01-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 196204-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-Piperidin-4-yl-benzoic acid is used as a chemical intermediate for the synthesis of various pharmaceutical drugs. Its presence in the structure of many drugs suggests that it may play a role in the development of new medications.
Used in Scientific Research:
4-Piperidin-4-yl-benzoic acid is used as a research compound in various scientific studies. Its properties and interactions with other compounds can provide valuable insights into the development of new chemical entities and their potential applications in different fields.

InChI:InChI=1/C12H15NO2/c14-12(15)11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2,(H,14,15)

Upstream product

• 32245-87-7 1-(4-Phenyl-piperidin-1-yl)-ethanone 
• 4732-69-8 Chloro-oxo-acetic acid 
• 79-37-8 oxalyl dichloride 
• 149353-75-3 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid 
• 586-76-5 4-Bromobenzoic acid 
• 286961-15-7 benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1 (2H)-pyridinecarboxylate 
• 52721-82-1 C₁₃H₁₇NO 

Downstream Products

• 281235-04-9 methyl 4-(piperidine-4-yl)benzoate 
• 354813-49-3 4-(1-methylpiperidin-4-yl)benzoic acid 
• 1105973-52-1 4-(1-carbamoyl-piperidin-4-yl)-benzoic acid 
• 1254948-83-8 C₁₈H₁₆F₆N₂O₃S 
• 1331747-36-4 4-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)benzoyl chloride 
• 1376437-10-3 propan-2-yl 2-butyl-3-({4-[1-(trifluoroacetyl)piperidin-4-yl]phenyl}carbonyl)indolizine-7-carboxylate 
• 1376437-11-4 3-({4-[1-(tert-butoxycarbonyl)piperidin-4-yl]phenyl}carbonyl)-2-butylindolizine-7-carboxylic acid 
• 354813-38-0 4-(1-(2-methoxyethyl)piperidin-4-yl)benzoic acid 
• 1376437-09-0 4-[1-(trifluoroacetyl)piperidin-4-yl]benzoic acid 

Relevant articles and documents

BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS

The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities

A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes.

CYSTEINE PROTEASE INHIBITORS

A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Dipeptide nitrile cathepsin K inhibitors

Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 toget